Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Pfizer's reported interest in acquiring sickle ... and made an $11.6 billion takeover bid for Biohaven and its migraine therapy Nurtec ODT (rimegepant).

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) diving into the opportunity to make effective and targeted ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Biohaven has a 52-week low of $26.80 and a 52-week high of $62.21. Biohaven ( NYSE:BHVN – Get Free Report ) last announced its earnings results on Monday, March 3rd.

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...